<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39395922</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8229</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Infectious diseases and therapy</Title><ISOAbbreviation>Infect Dis Ther</ISOAbbreviation></Journal><ArticleTitle>Respiratory Syncytial Virus Risk Profile in Hospitalized Infants and Comparison with Influenza and COVID-19 Controls in Valladolid, Spain, 2010-2022.</ArticleTitle><Pagination><StartPage>2395</StartPage><EndPage>2413</EndPage><MedlinePgn>2395-2413</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40121-024-01058-2</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">We aimed to describe the risk profile of RSV infections among children aged ≤ 24 months in Valladolid from January 2010 to August 2022 and to compare them with influenza and COVID-19 controls.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective cohort study of all laboratory-confirmed RSV, influenza, and COVID-19 infections. We analyzed risk factors for RSV hospitalization and severity (length-of-stay ≥ 8 days, intensive-care-unit admission, in-hospital death or readmission &lt; 30 days) and compared severity between hospitalized RSV patients vs. influenza and COVID-19 controls using multivariable logistic regression models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 1507 patients with RSV (1274 inpatient), 32 with influenza, and 52 COVID-19 controls. Hospitalized RSV (mean age 5.3 months) and COVID-19 (4 months) were younger than influenza (9.1 months) patients. Sixteen percent of patients had RSV within the first month of life. Most infants did not have comorbidities (74% RSV, 56% influenza, and 69% COVID-19). Forty-one percent of patients with RSV and influenza were coinfected vs. 27% COVID-19 (p = 0.04). Among RSV, hospitalization risk factors were prematurity (adjusted OR 3.11 [95% CI 1.66, 4.44]) and coinfection (2.03 [1.45, 2.85]). Risks for higher severity were maternal smoking (1.89 [1.07, 3.33]), prematurity (2.31 [1.59, 3.34]), chronic lung disease (2.20 [1.06, 4.58]), neurodevelopmental condition (4.28 [2.10, 8.73]), and coinfection (2.67 [2.09, 3.40]). Breastfeeding was protective against hospitalization (0.87 [0.80, 0.95]) and severity (0.81 [0.74, 0.88]), while complete vaccination schedule was protective against severity (0.51 [0.27, 0.97]). RSV had 2.47 (1.03, 5.96) higher risk of experiencing any severe outcome compared to influenza and did not show significant differences vs. COVID-19.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">RSV hospitalizations were more frequent and severe than influenza, while severity was comparable to the early pandemic COVID-19. Currently, both influenza and COVID-19 vaccines are included in the maternal and childhood Spanish immunization schedule between the ages of 6 and 59 months. RSV monoclonal antibody is recommended for ≤ 6 months but a third of patients were aged 6-24 months. Maternal RSV vaccination can protect their children directly from birth and indirectly through breastfeeding.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haeberer</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1708-870X</Identifier><AffiliationInfo><Affiliation>Pfizer SLU/Inc, Av Europa 20B, 28108, Madrid, Spain. mariana.haeberer@pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mengel</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Independent Consultant, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Pfizer SLU/Inc, Av Europa 20B, 28108, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toquero-Asensio</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Influenza Centre, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Estudios de Ciencias de La Salud de Castilla y León, ICSCYL, Soria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin-Toribio</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Influenza Centre, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Pfizer SLU/Inc, Av Europa 20B, 28108, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yongzheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Pfizer SLU/Inc, Av Europa 20B, 28108, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uppal</LastName><ForeName>Sonal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pfizer SLU/Inc, Av Europa 20B, 28108, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojo-Rello</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Influenza Centre, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Clínico Universitario de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domínguez-Gil</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Influenza Centre, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Clínico Universitario de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernán-García</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Influenza Centre, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Clínico Universitario de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernández-Espinilla</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>National Influenza Centre, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Clínico Universitario de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atwell</LastName><ForeName>Jessica E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Pfizer SLU/Inc, Av Europa 20B, 28108, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanz</LastName><ForeName>Javier Castrodeza</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>National Influenza Centre, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Clínico Universitario de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eiros</LastName><ForeName>José M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>National Influenza Centre, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Clínico Universitario de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanz-Muñoz</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>National Influenza Centre, Valladolid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Estudios de Ciencias de La Salud de Castilla y León, ICSCYL, Soria, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Dis Ther</MedlineTA><NlmUniqueID>101634499</NlmUniqueID><ISSNLinking>2193-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hospitalization</Keyword><Keyword MajorTopicYN="N">Infants</Keyword><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">Premature infants</Keyword><Keyword MajorTopicYN="N">Respiratory syncytial virus</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Mariana Haeberer, Rong Fan, Qing Liu, Sonal Uppal and Jessica Atwell are employees of Pfizer and may own Pfizer stock. Marina Toquero Asensio, Alejandro Martín Toribio, Silvia Rojo Rello, Marta Domínguez Gil, Cristina Hernán García, Virginia Fernández Espinilla, José M. Eiros, Javier Castrodeza Sanz, and Ivan Sanz-Muñoz received funding from Pfizer for data abstraction, protocol, and manuscript review. Alejandro Martín Toribio received funding by the call for UVa 2023 predoctoral contracts, co-funded by Banco Santander.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>23</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39395922</ArticleId><ArticleId IdType="pmc">PMC11499554</ArticleId><ArticleId IdType="doi">10.1007/s40121-024-01058-2</ArticleId><ArticleId IdType="pii">10.1007/s40121-024-01058-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7613574</ArticleId><ArticleId IdType="pubmed">35598608</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Li Y, Shi T, Bont LJ, Chu HY, Zar HJ, et al. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data. Lancet Lond Engl. 2024;403(10433):1241–53.</Citation><ArticleIdList><ArticleId IdType="pubmed">38367641</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeberer M, Bruyndonckx R, Polkowska-Kramek A, Torres A, Liang C, Nuttens C, et al. Estimated respiratory syncytial virus-related hospitalizations and deaths among children and adults in Spain, 2016–2019. Infect Dis Ther. 2024;13(3):463–80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10965866</ArticleId><ArticleId IdType="pubmed">38319540</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinón-Torres F, Carmo M, Platero L, Drago G, López-Belmonte JL, Bangert M, et al. Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015–2018. BMC Infect Dis. 2023;23(1):385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10249572</ArticleId><ArticleId IdType="pubmed">37291530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Luna M, Elola FJ, Fernandez-Perez C, Bernal JL, Lopez-Pineda A. Trends in respiratory syncytial virus bronchiolitis hospitalizations in children less than 1 year: 2004–2012. Curr Med Res Opin. 2016;32(4):693–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26709735</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Fernández JM, Hernández-Yuste A, Gutiérrez-Bedmar M, Cordón Martínez AM, Moreno-Pérez D. Does exposure of pregnant women to epidemic respiratory syncytial virus affect the severity of bronchiolitis? Enfermedades Infecc Microbiol Clínica. 2019;37(4):251–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">30100097</ArticleId></ArticleIdList></Reference><Reference><Citation>Suss RJ, Simões EAF. Respiratory syncytial virus hospital-based burden of disease in children younger than 5 years, 2015–2022. JAMA Netw Open. 2024;7(4): e247125.</Citation><ArticleIdList><ArticleId IdType="pubmed">38635270</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunziata F, Salomone S, Catzola A, Poeta M, Pagano F, Punzi L, et al. Clinical presentation and severity of SARS-CoV-2 infection compared to respiratory syncytial virus and other viral respiratory infections in children less than two years of age. Viruses. 2023;15(3):717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10055850</ArticleId><ArticleId IdType="pubmed">36992426</ArticleId></ArticleIdList></Reference><Reference><Citation>Piñana M, González-Sánchez A, Andrés C, Vila J, Creus-Costa A, Prats-Méndez I, et al. Genomic evolution of human respiratory syncytial virus during a decade (2013–2023): bridging the path to monoclonal antibody surveillance. J Infect. 2024;88(5): 106153.</Citation><ArticleIdList><ArticleId IdType="pubmed">38588960</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero-del-Cueto F, Ramos-Fernandez JM, Leiva-Gea I, Reina-Moreno E, Ortiz-Ortigosa A, Carazo-Gallego B, et al. Bronchiolitis before and after the SARS-CoV-2 pandemic: twelve years of experience in a Spanish paediatric hospital. Pediatr Pulmonol. 2023;58(4):1201–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">36653064</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodríguez-Fernández R, González-Martínez F, Perez-Moreno J, González-Sánchez MI, De La Mata NS, Toledo Del Castillo B, et al. Clinical phenotype of respiratory syncytial virus bronchiolitis before and during the coronavirus disease 2019 pandemic. Am J Perinatol. 2022;2:2.</Citation><ArticleIdList><ArticleId IdType="pubmed">36543242</ArticleId></ArticleIdList></Reference><Reference><Citation>Olguin TCP, Mazagatos C, Galindo-Carretero S, Vega-Piris L, Lozano-Álvarez M, Pérez-Gimeno G, et al. Epidemiología y carga de enfermedad por VRS en España. SiVIRA, temporadas 2021–22 y 2022–23. Bol Epidemiológico Sem. 2024;32(1):21–35.</Citation></Reference><Reference><Citation>Mineva GM, Purtill H, Dunne CP, Philip RK. Impact of breastfeeding on the incidence and severity of respiratory syncytial virus (RSV)-associated acute lower respiratory infections in infants: a systematic review highlighting the global relevance of primary prevention. BMJ Glob Health. 2023;8(2): e009693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906265</ArticleId><ArticleId IdType="pubmed">36746518</ArticleId></ArticleIdList></Reference><Reference><Citation>Dallagiacoma G, Arthur Rhedin S, Odone A, Alfvén T. A comparative analysis of non-pharmaceutical interventions for preventing the respiratory syncytial virus in 30 European countries. Acta Paediatr. 2024;113(6):1388–95.</Citation><ArticleIdList><ArticleId IdType="pubmed">38453683</ArticleId></ArticleIdList></Reference><Reference><Citation>McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459498</ArticleId><ArticleId IdType="pubmed">23618766</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451–64.</Citation><ArticleIdList><ArticleId IdType="pubmed">37018474</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazur NI, Terstappen J, Baral R, Bardají A, Beutels P, Buchholz UJ, et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2023;23(1):e2-21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9896921</ArticleId><ArticleId IdType="pubmed">35952703</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejias A, Rodríguez-Fernández R, Oliva S, Peeples ME, Ramilo O. The journey to a respiratory syncytial virus vaccine. Ann Allergy Asthma Immunol. 2020;125(1):36–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7311299</ArticleId><ArticleId IdType="pubmed">32217187</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang Y, Lu H, Cao D, Zhu X, Long Q, Tian F, et al. Efficacy, immunogenicity and safety of respiratory syncytial virus prefusion F vaccine: systematic review and meta-analysis. BMC Public Health. 2024;24(1):1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11075318</ArticleId><ArticleId IdType="pubmed">38711074</ArticleId></ArticleIdList></Reference><Reference><Citation>Álvarez Aldean J, Rivero Calle I, Rodríguez Fernández R, Aceituno Mata S, Bellmunt A, Prades M, et al. Cost-effectiveness analysis of maternal immunization with RSVpreF vaccine for the prevention of respiratory syncytial virus among infants in Spain. Infect Dis Ther. 2024;13(6):1315–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11128416</ArticleId><ArticleId IdType="pubmed">38733493</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837–46.</Citation><ArticleIdList><ArticleId IdType="pubmed">35235726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health of Spain. Recomendaciones de utilización de nirsevimab para la temporada 2024–2025 en España [Internet]. 2024 [cited 2024 Jul 3]. Available from: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/Nirsevimab.pdf</Citation></Reference><Reference><Citation>Ministry of Health of Spain. National Immunization Calendar [Internet]. 2024. Available from: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/calendario/docs/CalendarioVacunacion_Todalavida.pdf</Citation></Reference><Reference><Citation>Haeberer M, Mengel M, Fan R, Toquero-Asensio M, Martin-Toribio A, Liu Q, et al. RSV Risk profile in hospitalized adults and comparison with influenza and COVID-19 controls in Valladolid, Spain, 2010–2022. Infect Dis Ther. 2024. 10.1007/s40121-024-01021-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11343947</ArticleId><ArticleId IdType="pubmed">39033476</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health of Spain. Recomendaciones de vacunación frente a gripe y COVID-19 en la temporada 2023–2024 en España. Actualización [Internet]. 2024. Available from: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/gripe_covid19/docs/RecomendacionesVacunacion_Gripe-Covid19.pdf</Citation></Reference><Reference><Citation>Meyer M, Ruebsteck E, Eifinger F, Klein F, Oberthuer A, Van Koningsbruggen-Rietschel S, et al. Morbidity of respiratory syncytial virus (RSV) infections: RSV compared with severe acute respiratory syndrome coronavirus 2 infections in children aged 0–4 years in Cologne, Germany. J Infect Dis. 2022;226(12):2050–3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903412</ArticleId><ArticleId IdType="pubmed">35172330</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi S, Al-Sayyed B, Gladfelter TR. Comparative epidemiology, hospital course, and outcomes of viral respiratory infections in hospitalized pediatric patients. Indian J Med Microbiol. 2021;39(1):24–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33610252</ArticleId></ArticleIdList></Reference><Reference><Citation>Law A, Sato R, López-Ibáñez de Aldecoa A, Seabroke S, Ramirez Agudelo J, Mora L, Sarabia L, Meroc E, Aponte-Torres Z, Haeberer M. Economic burden of hospitalized respiratory syncytial virus infection among children in Spain, 2016–2019 [Internet]. Available from: https://www.ispor.org/docs/default-source/euro2023/eu-ispor-posterchildren-spain-rsv-cost-studyv4131832-pdf.pdf?sfvrsn=163ce052_0</Citation></Reference><Reference><Citation>Miron VD, Raianu RO, Filimon C, Craiu M. Clinical differences between SARS-CoV-2 and RSV infections in infants: findings from a case-control study. Viruses. 2023;16(1):63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10819890</ArticleId><ArticleId IdType="pubmed">38257763</ArticleId></ArticleIdList></Reference><Reference><Citation>Cilla G, Sarasua A, Montes M, Arostegui N, Vicente D, Pérez-Yarza E, et al. Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country. Spain Epidemiol Infect. 2006;134(3):506–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2870431</ArticleId><ArticleId IdType="pubmed">16638164</ArticleId></ArticleIdList></Reference><Reference><Citation>Vila J, Lera E, Andrés C, Piñana M, Rello-Saltor V, Tobeña-Rué M, et al. The burden of non-SARS-CoV2 viral lower respiratory tract infections in hospitalized children in Barcelona (Spain): a long-term, clinical, epidemiologic and economic study. Influenza Other Respir Viruses. 2023;17(1): e13085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9835422</ArticleId><ArticleId IdType="pubmed">36541036</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Cañete M, Moreno-Pérez D, Jurado-Ortiz A, García-Martín FJ, López-Siles J, Olalla-Martín L. El virus de la gripe en pediatría. Un motivo de hospitalización. Enfermedades Infecc Microbiol Clínica. 2007;25(3):177–83.</Citation><ArticleIdList><ArticleId IdType="pubmed">17335696</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Diaz A, Garcia-Maurino C, Jordan-Villegas A, Naples J, Ramilo O, Mejias A. Viral bacterial interactions in children: impact on clinical outcomes. Pediatr Infect Dis J. 2019;38(6S):S14–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6581203</ArticleId><ArticleId IdType="pubmed">31205238</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo C, Pozo F, García-García M, Sanchez M, Lopez-Valero M, Pérez-Breña P, et al. Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three-year prospective study. Acta Paediatr. 2010;99(6):883–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159545</ArticleId><ArticleId IdType="pubmed">20163373</ArticleId></ArticleIdList></Reference><Reference><Citation>Piñero Fernández JA, Alfayate Migueléz S, Menasalvas Ruiz A, Salvador García C, Moreno Docón A, Sánchez-Solís De Querol M. Características epidemiológicas, clínicas y terapéuticas de lactantes hospitalizados por bronquiolitis. An Pediatría. 2012;77(6):391–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105076</ArticleId><ArticleId IdType="pubmed">22726299</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedorczak A, Zielińska N, Nosek-Wasilewska P, Mikołajczyk K, Lisiak J, Zeman K, et al. Comparison of COVID-19 and RSV infection courses in infants and children under 36 months hospitalized in paediatric department in fall and winter season 2021/2022. J Clin Med. 2022;11(23):7088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9741168</ArticleId><ArticleId IdType="pubmed">36498663</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Z, Yan X, Gao L, Ding S, Bai Y, Zheng Y, et al. Comparison of clinical characteristics among COVID-19 and non-COVID-19 pediatric pneumonias: a multicenter cross-sectional study. Front Cell Infect Microbiol. 2021;1(11): 663884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8281119</ArticleId><ArticleId IdType="pubmed">34277466</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkan Ozdemir S, Soysal B, Calkavur S, Gökmen Yıldırım T, Kıymet E, Kalkanlı O, et al. Is respiratory syncytial virus infection more dangerous than COVID 19 in the neonatal period? J Matern Fetal Neonatal Med. 2022;35(22):4398–403.</Citation><ArticleIdList><ArticleId IdType="pubmed">33225779</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbonell-Estrany X, Figueras-Aloy J, Law BJ, Stud IRI por VRSSGICN on I in C. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J. 2004;23(11):193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15577573</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzoni P, Viora E, Lanari M, Iantomasi R, Montuori EA, Rodgers-Gray B, et al. Maternal risk factors for respiratory syncytial virus lower respiratory tract infection in otherwise healthy preterm and term infants: a systematic review and meta-analysis. Pediatr Infect Dis J [Internet]. 2024 May 15 [cited 2024 Jul 9]; Available from: https://journals.lww.com/10.1097/INF.0000000000004387</Citation><ArticleIdList><ArticleId IdType="pubmed">38754000</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Fernández JM, Moreno-Pérez D, Gutiérrez-Bedmar M, Hernández-Yuste A, Cordón-Martínez AM, Milano-Manso G, et al. [Prediction of Severe Course in Infants with RSV Bronchiolitis under 6 Months. Spain]. Rev Esp Salud Publica. 2017;91:e201701006.</Citation><ArticleIdList><ArticleId IdType="pubmed">28104904</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueras-Aloy J, Manzoni P, Paes B, Simões EAF, Bont L, Checchia PA, et al. Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among preterm infants without chronic lung disease or congenital heart disease. Infect Dis Ther. 2016;5(4):417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5125133</ArticleId><ArticleId IdType="pubmed">27628014</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbonell-Estrany X, Fullarton JR, Gooch KL, Vo PG, Figueras-Aloy J, Lanari M, et al. Effects of parental and household smoking on the risk of respiratory syncytial virus (RSV) hospitalisation in late-preterm infants and the potential impact of RSV prophylaxis. J Matern Fetal Neonatal Med. 2013;26(9):926–31.</Citation><ArticleIdList><ArticleId IdType="pubmed">23379728</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueras Aloy J, Quero J. Recomendaciones para la prevención de la infección por virus respiratorio sincitial. An Pediatría. 2005;63(4):357–62.</Citation><ArticleIdList><ArticleId IdType="pubmed">16219256</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo C, García-García ML, Blanco C, Vázquez MC, Frías ME, Pérez-Breña P, et al. Multiple simultaneous viral infections in infants with acute respiratory tract infections in Spain. J Clin Virol. 2008;42(3):268–72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108242</ArticleId><ArticleId IdType="pubmed">18455958</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Pillai P, Miyake F, Nair H. The role of viral co-infections in the severity of acute respiratory infections among children infected with respiratory syncytial virus (RSV): a systematic review and meta-analysis. J Glob Health. 2020;10(1): 010426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7295447</ArticleId><ArticleId IdType="pubmed">32566164</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Fernandez R, González-Sánchez MI, Perez-Moreno J, González-Martínez F, De La Mata NS, Mejias A, et al. Age and respiratory syncytial virus etiology in bronchiolitis clinical outcomes. J Allergy Clin Immunol Glob. 2022;1(3):91–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10509905</ArticleId><ArticleId IdType="pubmed">37781264</ArticleId></ArticleIdList></Reference><Reference><Citation>Brigadoi G, Demarin GC, Boracchini R, Pierantoni L, Rossin S, Barbieri E, et al. Comparison between the viral illness caused by SARS-CoV-2, influenza virus, respiratory syncytial virus and other respiratory viruses in pediatrics. Viruses. 2024;16(2):199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10891516</ArticleId><ArticleId IdType="pubmed">38399975</ArticleId></ArticleIdList></Reference><Reference><Citation>Peláez A, Ruiz Del Árbol N, Vázquez Sellán A, Castellano JM, Soriano JB, Ancochea J, et al. Clinical characteristics and outcomes among hospitalised COVID-19 patients across epidemic waves in Spain: an unCoVer analysis. Med Clin (Barc). 2024;162(11):523–31.</Citation><ArticleIdList><ArticleId IdType="pubmed">38555273</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl A, Mielke N, Johnson S, Desai A, Qu L. Severe COVID-19 outcomes in pediatrics: an observational cohort analysis comparing alpha, delta, and omicron variants. Lancet Reg Health - Am. 2023;18: 100405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714340</ArticleId><ArticleId IdType="pubmed">36474521</ArticleId></ArticleIdList></Reference><Reference><Citation>Alteri C, Scutari R, Costabile V, Colagrossi L, La Rosa KY, Agolini E, et al. Publisher Correction: Epidemiological characterization of SARS-CoV-2 variants in children over the four COVID-19 waves and correlation with clinical presentation. Sci Rep. 2022;12(1):12814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9326428</ArticleId><ArticleId IdType="pubmed">35896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Pino R, Antoñanzas JM, Paredes-Carmona F, Perramon A, Rivière JG, Coma M, et al. Multisystem inflammatory syndrome in children and SARS-CoV-2 variants: a two-year ambispective multicentric cohort study in Catalonia. Spain Eur J Pediatr. 2023;182(4):1897–909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9937862</ArticleId><ArticleId IdType="pubmed">36801975</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedenmann M, Ipekci AM, Araujo-Chaveron L, Prajapati N, Lam YT, Alam MI, et al. SARS-CoV-2 variants of concern in children and adolescents with COVID-19: a systematic review. BMJ Open. 2023;13(10): e072280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10565293</ArticleId><ArticleId IdType="pubmed">37813543</ArticleId></ArticleIdList></Reference><Reference><Citation>Rios-Guzman E, Simons LM, Dean TJ, Agnes F, Pawlowski A, Alisoltanidehkordi A, et al. Deviations in RSV epidemiological patterns and population structures in the United States following the COVID-19 pandemic. Nat Commun. 2024;15(1):3374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11032338</ArticleId><ArticleId IdType="pubmed">38643200</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall CB, Walsh EE, Schnabel KC, Long CE, McConnochie KM, Hildreth SW, et al. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis. 1990;162(6):1283–90.</Citation><ArticleIdList><ArticleId IdType="pubmed">2230258</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafri HS, Wu X, Makari D, Henrickson KJ. Distribution of respiratory syncytial virus subtypes A and B among infants presenting to the emergency department with lower respiratory tract infection or apnea. Pediatr Infect Dis J. 2013;32(4):335–40.</Citation><ArticleIdList><ArticleId IdType="pubmed">23337904</ArticleId></ArticleIdList></Reference><Reference><Citation>Vila J, Lera E, Peremiquel-Trillas P, Andrés C, Martínez L, Barceló I, et al. Increased RSV-A bronchiolitis severity in RSV-infected children admitted to a reference center in Catalonia (Spain) between 2014 and 2018. J Pediatr Infect Dis Soc. 2023;12(3):180–3.</Citation><ArticleIdList><ArticleId IdType="pubmed">36744919</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmdahl I, Bents SJ, Baker RE, Casalegno JS, Trovão NS, Park SW, et al. Differential impact of COVID-19 non-pharmaceutical interventions on the epidemiological dynamics of respiratory syncytial virus subtypes A and B. Sci Rep. 2024;14(1):14527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11196647</ArticleId><ArticleId IdType="pubmed">38914626</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raya B, Viñeta Paramo M, Reicherz F, Lavoie PM. Why has the epidemiology of RSV changed during the COVID-19 pandemic? eClinicalMedicine. 2023;61: 102089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10359735</ArticleId><ArticleId IdType="pubmed">37483545</ArticleId></ArticleIdList></Reference><Reference><Citation>Cebey-López M, Pardo-Seco J, Gómez-Carballa A, Martinón-Torres N, Martinón-Sánchez JM, Justicia-Grande A, et al. Bacteremia in children hospitalized with respiratory syncytial virus infection. PLoS ONE. 2016;11(2): e0146599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752219</ArticleId><ArticleId IdType="pubmed">26872131</ArticleId></ArticleIdList></Reference><Reference><Citation>Mineva G, Philip R. Impact of breastfeeding on the incidence and severity of respiratory syncytial virus bronchiolitis in infants: systematic review. Rural Remote Health. 2023;23(1):8088.</Citation><ArticleIdList><ArticleId IdType="pubmed">36802679</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>